Numerous attempts have been made with multiple GLP-1 secretagogues such as GPR119 agonists (239) but so far no compound has reached the market because of bioavailability issues and systemic off-target toxicity
Neglecting these pillars while relying solely on supplements is akin to adding expensive furniture to a crumbling house
J Appl Microbiol 115(1):4149 Sulaiman GM, Adhiah AH, Al-Sammarrae KW, Bagnati R, Frapolli R, Bello E, Uboldi S, Romano M, Panini N, Scanziani E, Pezzolato M (2012) Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo
Local manufacturing initiatives and regional pricing models improve accessibility to GLP-1 therapies
Being backed by years of research makes it a perfect choice for skin-brightening benefits